References
- Kaliki S, Shields CL. Uveal melanoma: relatively rare but deadly cancer. Eye (Lond) 2017; 31: 241-57. doi: 10.1038/eye.2016.275
- Elder DE, Bastian BC, Cree IA, Massi D, Scolyer RA. The 2018 World Health Organization classification of cutaneous, mucosal, and uveal melanoma: detailed analysis of 9 distinct subtypes defined by their evolutionary pathway. Arch Pathol Lab Med 2020; 144: 500-22. doi: 10.5858/arpa.2019-0561-RA
- Sathe S, Sakata M, Beaton AR, Sack RA. Identification, origins and the diurnal role of the principal serine protease inhibitors in human tear fluid. Curr Eye Res 1998; 17: 348-62. doi: 10.1080/02713689808951215
- Saakyan SV, Tsygankov АY, Moiseeva NI, Karamysheva АF, Garri DD. Assessment of the chemosensitivity of uveal melanoma cells ex vivo Bull Exp Biol Med 2020; 170: 142-7. doi: 10.1007/s10517-020-05020-3
- Shah SU, Mashayekhi A, Shields CL, Walia HS, Hubbard GB 3rd, Zhang J, et al. Uveal metastasis from lung cancer: clinical features, treatment, and outcome in 194 patients. Ophthalmology 2014; 121: 352-7. doi: 10.1016/j. ophtha.2013.07.014
- Valsecchi ME, Orloff M, Sato R, Chervoneva I, Shields CL, Shields JA, et al. Adjuvant sunitinib in high-risk patients with uveal melanoma: comparison with institutional controls. Ophthalmology 2018; 125: 210-7. doi: 10.1016/j. ophtha.2017.08.017
- Spagnolo F, Caltabiano G, Queirolo P. Uveal melanoma. Cancer Treat Rev 2012; 38: 549-53. doi: 10.1016/j.ctrv.2012.01.002
- Luke JJ, Triozzi PL, McKenna KC, Van Meir EG, Gershenwald JE, Bastian BC, et al. Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res 2015; 28: 135-47. doi: 10.1111/ pcmr.12304
- Turk V, Stoka V, Turk D. Cystatins: biochemical and structural properties, and medical relevance. Front Biosci 2008; 13: 5406-20. doi: 10.2741/3089
- Breznik B, Mitrović A, Lah T, Kos J. Cystatins in cancer progression: more than just cathepsin inhibitors. Biochimie 2019; 166: 233-50. doi: 10.1016/j. biochi.2019.05.002
- Wu H, Du Q, Dai Q, Ge J, Cheng X. Cysteine protease cathepsins in atherosclerotic cardiovascular diseases. J Atheroscler Thromb 2018; 25: 111-23. doi: 10.5551/jat.RV17016
- Wallin H, Bjarnadottir M, Vogel LK, Wassélius J, Ekström U, Abrahamson M. Cystatins – extra- and intracellular cysteine protease inhibitors: high-level secretion and uptake of cystatin C in human neuroblastoma cells. Biochimie 2010; 92: 1625-34. doi: 10.1016/j.biochi.2010.08.011
- Liu Y, Yao J. Research progress of cystatin SN in cancer. Onco Targets Ther 2019; 12: 3411-9. doi: 10.2147/OTT.S194332
- Grubb AO. Cystatin C – properties and use as diagnostic marker. Adv Clin Chem 2000; 35: 63-99. doi: 10.1016/s0065-2423(01)35015-1
- Abrahamson M, Alvarez-Fernandez M, Nathanson CM. Cystatins. Biochem Soc Symp 2003; 70: 179-99. doi: 10.1042/bss0700179
- Poteryaeva ON, Falameyeva OV, Korolenko TA, Kaledin VI, Djanayeva SJ, Nowicky JW, et al. Cysteine proteinase inhibitor level in tumor and normal tissues in control and cured mice. Drugs Exp Clin Res 2000; 26: 301-6. PMID: 11345042
- Keppler D. Towards novel anti-cancer strategies based on cystatin function. Cancer Lett 2006; 235: 159-76. doi: 10.1016/j.canlet.2005.04.001
- Lah TT, Kokalj-Kunovar M, Drobnic-Kosorok M, Babnik J, Golouh R, Vrhovec I, et al. Cystatins and cathepsins in breast carcinoma. Biol Chem Hoppe Seyler 1992; 373: 595-604. doi: 10.1515/bchm3.1992.373.2.595
- Cox JL. Cystatins and cancer. Front Biosci (Landmark Ed) 2009; 14: 463-74. doi: 10.2741/3255. PMID: 19273078
- Jakoš T, Pišlar A, Jewett A, Kos J. Cysteine cathepsins in tumor-associated immune cells. Front Immunol 2019; 10: 2037. doi: 10.3389/fimmu.2019.02037
- Svechnikova IG, Korolenko TA, Stashko JuF, Kaledin VI, Nikolin VP, Nowicky JW. The influence of Ukrain on the growth of HA-1 tumor in mice: the role of cysteine proteinases as markers of tumor malignancy. Drugs Exp Clin Res 1998; 24: 261-9. PMID: 10190085
- Korolenko TA, Cherkanova MS, Gashenko EA, Johnston T. Cystatin C, atherosclerosis and lipid-lowering therapy by statins. In: Cohen JB, Ryseck LP, editors. Cystatins: protease inhibitors, biomarkers and immunomodulators. New York, USA: Nova Science Publishers; 2011. p. 187-204.
- Korolenko TA, Pisareva EE, Filyushina EE, Johnston TP, Machova E. Serum cystatin C and chitotriosidase in acute P-407 induced dyslipidemia: can they serve as potential early biomarkers for atherosclerosis? Exp Toxicol Pathol 2015; 67: 459-66. doi: 10.1016/j.etp.2015.06.003
- Paraoan L, Gray D, Hiscott P, Garcia-Finana M, Lane B, Damato B, et al. Cathepsin S and its inhibitor cystatin C: imbalance in uveal melanoma. Front Biosci (Landmark Ed.) 2009; 14: 2504-13. doi: 10.2741/3393
- De Souza GA, Godoy LM, Mann M. Identification of 491 proteins in the tear fluid proteome reveals a large number of proteases and protease inhibitors. Genome Biol 2006; 7: R72. doi: 10.1186/gb-2006-7-8-R72
- Balasubramanian SA, Wasinger VC, Pye DC, Willcox MD. Preliminary identification of differentially expressed tear proteins in keratoconus. Mol Vis 2013; 19: 2124-34. eCollection 2013. PMID: 24194634
- Dikovskaya MA, Trunov AN, Chernykh VV, Korolenko TA. Cystatin C and lactoferrin concentrations in biological fluids as possible prognostic factors in eye tumor development. Int J Circumpolar Health 2013; 72(Suppl 1): 21087. doi: 10.3402/ijch.v72i0.21087. eCollection 2013
- Korolenko TA, Tuzikov FV, Cherkanova MS, Johnston TP, Tuzikova NA, Loginova VM, et al. Influence of atorvastatin and carboxymethylated glucan on the serum lipoprotein profile and MMP activity of mice with lipemia induced by poloxamer 407. Can J Physiol Pharmacol 2012; 90: 141-53. doi: 10.1139/y11-118
- Pišlar A, Jewett A, Kos J. Cysteine cathepsins: their biological and molecular significance in cancer stem cells. Semin Cancer Biol 2018; 53: 168-77. doi: 10.1016/j.semcancer.2018.07.010
- Jiang J, Liu HL, Liu ZH, Tan SW, Wu B. Identification of cystatin SN as a novel biomarker for pancreatic cancer. Tumor Biol 2015; 36: 3903-10. doi: 10.1007/s13277-014-3033-3
- Jiang Y, Zhang J, Zhang C, Hong L, Jiang Y, Lu L, et al. The role of cystatin C as a proteosome inhibitor in multiple myeloma. Hematology 2020; 25: 457-63. doi: 10.1080/16078454.2020.1850973
- Leto G, Sepporta MV. The potential of cystatin C as a predictive biomarker in breast cancer. Expert Rev Anticancer Ther 2020; 20: 1049-56. doi: 10.1080/14737140.2020.1829481
- Ognibene A, Mannucci E, Caldini A, Terreni A, Brogi M, Bardini G, et al. Cystatin C reference values and aging. Clin Biochem 2006; 39: 658-61. doi: 10.1016/j.clinbiochem.2006.03.017
- Odden MC, Tager IB, Gansevoort RT, Bakker SJ, Katz R, Fried LF, et al. Age and cystatin C in healthy adults: a collaborative study. Nephrol Dial Transplant 2010; 25: 463-9. doi: 10.1093/ndt/gfp474
- Edinga BE, Yakam AT, Nansseu JR, Bilong C, Belinga S, Minkala E, et al. Reference intervals for serum cystatin C and serum creatinine in an adult sub-Saharan African population. BMC Clin Pathol 2019; 19: 4. doi: 10.1186/ s12907-019-0086-7
- Groesbeck D, Köttgen A, Parekh R, Selvin E, Schwartz GJ, Coresh J, et al. Age, gender, and race effects on cystatin C levels in US adolescents. Clin J Am Soc Nephrol 2008; 3: 1777-85. doi: 10.2215/CJN.00840208
- Zou J, Chen Z, Wei X, Chen Z, Fu Y, Yang X, et al. Cystatin C as a potential therapeutic mediator against Parkinson’s disease via VEGF-induced angiogenesis and enhanced neuronal autophagy in neurovascular units. Cell Death Dis 2017; 8: e2854. doi: 10.1038/cddis.2017.240
- Keppler D, Zhang J, Bihani T, Lin AW. Novel expression of CST1 as candidate senescence marker. J Gerontol A Biol Sci Med Sci 2011; 66: 723-31. doi: 10.1093/gerona/glr033
- Wang R, Chen Z, Fu Y, Wei X, Liao J, Liu X, et al. Plasma cystatin C and high-density lipoprotein are important biomarkers of Alzheimer’s disease and vascular dementia: a cross-sectional study. Front Aging Neurosci 2017; 9: 26. doi: 10.3389/fnagi.2017.00026
- Xu Y, Ding Y, Li X, Wu X. Cystatin C is a disease-associated protein subject to multiple regulation. Immunol Cell Biol 2015; 93: 442-51. doi: 10.1038/ icb.2014.121
- Kos J, Mitrović A, Mirković B. The current stage of cathepsin B inhibitors as potential anticancer agents. Future Med Chem 2014; 6: 1355-71. doi: 10.4155/fmc.14.73
- Pieragostino D, D’Alessandro M, Di Ioia M, Di Ilio C, Sacchetta P, Del Boccio P. Unraveling the molecular repertoire of tears as a source of biomarkers: beyond ocular diseases. Proteomics Clin Appl 2015; 9: 169-86. doi: 10.1002/ prca.201400084
- Huh CG, Håkansson K, Nathanson CM, Thorgeirsson UP, Jonsson N, Grubb A, et al. Decreased metastatic spread in mice homozygous for a null allele of the cystatin C protease inhibitor gene. Mol Pathol 1999; 52: 332-40. doi: 10.1136/mp.52.6.332
- Wegiel B, Jiborn T, Abrahamson M, Helczynski L, Otterbein L, Persson JL, et al. Cystatin C is downregulated in prostate cancer and modulates invasion of prostate cancer cells via MAPK/Erk and androgen receptor pathways. PLoS ONE 2009; 4: e7953. doi: 10.1371/journal.pone.0007953
- Hammouda NE, Salah El-Din MA, El-Shishtawy MM, El-Gayar AM. Serum cystatin C as a biomarker in diffuse large B-cell lymphoma. Sci Pharm 2017; 85: 9. doi: 10.3390/scipharm85010009
- Cao X, Li Y, Luo RZ, Zhang L, Zhang SL, Zeng J, et al. Expression of cystatin SN significantly correlates with recurrence, metastasis, and survival duration in surgically resected non-small cell lung cancer patients. Sci Rep 2015; 5: 8230. doi: 10.1038/srep08230
- Chen YF, Ma G, Cao X, Luo RZ, He LR, He JH, et al. Overexpression of cystatin SN positively affects survival of patients with surgically resected esophageal squamous cell carcinoma. BMC Surg 2013; 13: 15. doi: 10.1186/1471-248213-15
- Oh SS, Park S, Lee KW, Madhi H, Park SG, Lee HG, et al. Extracellular cystatin SN and cathepsin B prevent cellular senescence by inhibiting abnormal glycogen accumulation. Cell Death Dis 2017; 8: e2729. doi: 10.1038/cddis.2017.153
- Oh BM, Lee SJ, Cho HJ, Park YS, Kim JT, Yoon SR, et al. Cystatin SN inhibits auranofin-induced cell death by autophagic induction and ROS regulation via glutathione reductase activity in colorectal cancer. Cell Death Dis 2017; 8: e2682. doi: 10.1038/cddis.2017.100
- Yoneda K, Iida H, Endo H, Hosono K, Akiyama T, Takahashi H, et al. Identification of cystatin SN as a novel tumor marker for colorectal cancer. Int J Oncol 2009; 35: 33-40. doi: 10.3892/ijo_00000310
- Cui Y, Sun D, Song R, Zhang S, Liu X, Wang Y, et al. Upregulation of cystatin SN promotes hepatocellular carcinoma progression and predicts a poor prognosis. J Cell Physiol 2019; 234: 22623-34. doi: 10.1002/jcp.28828
- Paraoan L, Hiscott P, Gosden C. Cystatin C in macular and neuronal degenerations: Implications for mechanism(s) of age-related macular degeneration. Vision Research 2010; 50: 737-42. doi: 10.1016/j.visres.2009.10.022